Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 12 - 09 save search
FMC Corporation signs agreements with Corteva Agriscience to provide growers seed treatment insecticides
Published: 2021-12-09 (Crawled : 23:00) - prnewswire.com
FMC A | $58.4 -0.43% -0.33% 190
|
Process Industries
|
| O: -0.25%
H: 0.0%
C: 0.0%
treatment
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
AUPH | $5.03 -1.18% -1.19% 690K
|
Health Technology
|
| O: 3.7%
H: 2.55%
C: -2.92%
treatment lupkynis topline results positive results topline lupus
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
CYTH | $1.3 7.44% 7.94% 21K
|
Professional, Scientific, and T...
|
| O: -1.49%
H: 3.9%
C: -2.6%
trappsol treatment ema ongoing therapeutics disease
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-09 (Crawled : 14:30) - globenewswire.com
INMB | News 0 d | $10.62 4.73% 4.38% 0
|
Health Technology
|
| O: -0.88%
H: 2.56%
C: -0.08%
treatment cancer breast cancer symposium
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -1.69%
H: 6.48%
C: 2.62%
vir-2218 treatment phase 2 hepatitis technology trial biotech infection iot infections chronic hepatitis b nivolumab
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
MBIO | $0.3501 -2.67% -2.77% 2.2K
|
Health Technology
|
| O: 2.88%
H: 1.87%
C: -3.27%
FBIO | $1.79 -1.11% -1.4% 120K
|
Health Technology
|
| O: 4.85%
H: 0.0%
C: 0.0%
mb-106 treatment leukemia potential lymphomas t-cell
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 10.22%
H: 1.36%
C: -2.71%
acer-801 treatment clearance therapeutics
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for AficamtenFDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM
Published: 2021-12-09 (Crawled : 13:00) - biospace.com/
CYTK | $66.82 1.91% 1.78% 1
|
Health Technology
|
| O: -2.93%
H: 0.0%
C: 0.0%
treatment fda cardio granted therapy results breakthrough therapy designation
Industrial Wastewater Treatment Chemicals Market worth $16.6 billion by 2026 - Exclusive Report by MarketsandMarkets™
Published: 2021-12-09 (Crawled : 12:30) - prnewswire.com
ECL | News | $220.78 0.51% 0.0% 56
|
Process Industries
|
| O: -0.2%
H: 0.25%
C: -0.26%
DOW | $56.98 0.42% -2.58% 4M
|
Process Industries
|
| O: -1.92%
H: 0.63%
C: 0.28%
treatment trial
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
Published: 2021-12-09 (Crawled : 12:00) - globenewswire.com
AFMD | $4.88 -8.79% -8.96% 61
|
Health Technology
|
| O: 4.4%
H: 0.44%
C: -9.16%
cd30 treatment blood positive oda
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: 0.82%
H: 0.29%
C: -1.35%
diagnostic treatment biopharma test t-cell
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
MTH | $154.69 -2.21% 7.56% 64
|
Consumer Durables
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.